ArticleFrontiers in immunology2026
The role of CSF IL-6 levels in diagnosis and outcome prediction of autoimmune encephalitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune encephalitis (AE) is clinically heterogeneous, and its early diagnosis and prognostication remain challenging. We aimed to determine whether cerebrospinal fluid (CSF) interleukin-6 (IL-6), a marker of central nervous system inflammation, can improve AE diagnosis and predict treatment outcomes. Methods: This retrospective cohort study (April 2014-August 2024) included patients who fulfilled the criteria for at least possible AE according to the 2016 Graus criteria and had their CSF IL-6 measured. The patients with infectious encephalitis were excluded. We collected clinical, laboratory, brain MRI, and tumor screening data. In a subset of AE patients with repeat CSF testing approximately 1 month after initiation of immunotherapy, we obtained post-treatment laboratory data, hospitalization length, and modified Rankin Scale (mRS) score at discharge. Diagnostic performance was assessed using receiver operating characteristic (ROC) analyses, and multivariable regression was used to identify predictors of discharge mRS score and hospitalization length. In antibody-negative AE, we also examined the association between post-treatment CSF IL-6 (CSF IL-6_1M) and the RAPID score, a prognostic tool for antibody-negative AE. Results: The cohort comprised 55 AE cases (25 antibody-positive). ROC analysis of CSF parameters suggested that IL-6 showed the highest sensitivity, whereas the immunoglobulin G (IgG) index demonstrated the highest specificity. In an additional analysis that included CSF IL-6 as an additional inflammatory CSF parameter within the 2016 Graus criteria, the diagnostic sensitivity increased from 73% to 85% with a specificity of 88%. Among the 35 AE patients with post-treatment CSF measurements, multivariable regression showed that only CSF IL-6_1M significantly predicted both mRS score at discharge (p = 0.0444, 95% CI 0.00104-0.0702) and hospitalization length (p = 0.0143, 95% CI 0.425-3.13). Specifically, patients with CSF IL-6_1M of < 6 pg/mL had significantly shorter hospital stays than those with higher levels (generalized Wilcoxon test, p = 0.0361). CSF IL-6_1M was also significantly associated with the RAPID score (p = 0.0492). Conclusion: CSF IL-6 is a useful marker for early AE diagnosis and CSF IL-6_1M may serve as a practical biomarker for treatment response and prognosis, particularly for antibody-negative AE. Thus, CSF IL-6 and CSF IL-6_1M assessment may facilitate more precise, timely, and individualized therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.